Oncogenesis (Nov 2021)

TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer

  • Yu-Ching Wen,
  • Yen-Nien Liu,
  • Hsiu-Lien Yeh,
  • Wei-Hao Chen,
  • Kuo-Ching Jiang,
  • Shian-Ren Lin,
  • Jiaoti Huang,
  • Michael Hsiao,
  • Wei-Yu Chen

DOI
https://doi.org/10.1038/s41389-021-00371-6
Journal volume & issue
Vol. 10, no. 11
pp. 1 – 11

Abstract

Read online

Abstract Neuroendocrine differentiation (NED) is associated with WNT signaling activation and can be significantly observed after failure of androgen-deprivation therapy (ADT) for prostatic adenocarcinomas. Cytokine signaling is stimulated in NED prostate cancer; however, how ADT-upregulated WNT signaling promotes activation of cytokine signaling and contributes to NED of prostate cancer is poorly understood. In this study, we identified ADT-mediated upregulation of transcription factor 7 like 1 (TCF7L1), which increases the cytokine response and enhances NED of prostate cancer through interleukin (IL)-8/C-X-C motif chemokine receptor type 2 (CXCR2) signaling activation. ADT induced the secretion of WNT4 which upon engagement of TCF7L1 in prostate cancer cells, enhanced IL-8 and CXCR2 expressions. TCF7L1 directly binds to the regulatory sequence region of IL-8 and CXCR2 through WNT4 activation, thus upregulating IL-8/CXCR2 signaling-driven NED and cell motility. Analysis of prostate tissue samples collected from small-cell neuroendocrine prostate cancer (SCPC) and castration-resistant prostate cancer (CRPC) tumors showed an increased intensity of nuclear TCF7L1 associated with CXCR2. Our results suggest that induction of WNT4/TCF7L1 results in increased NED and malignancy in prostate cancer that is linked to dysregulation of androgen receptor signaling and activation of the IL-8/CXCR2 pathway.